TY - CHAP PY - 2010 DA - 2010// TI - Health Systems Institutional Characteristics BT - OECD Health Working Papers PB - OECD CY - Paris ID - ref1 ER - TY - CHAP AU - Kanavos, P. PY - 2011 DA - 2011// BT - DIFFERENCES IN COSTS OF AND ACCESS TO PHARMACEUTICAL PRODUCTS IN THE EU. Study PB - European Parliament CY - POLICIES DGFI ed. Brussels, ID - Kanavos2011 ER - TY - JOUR AU - Adamski, J. AU - Godman, B. AU - Ofierska-Sujkowska, G. AU - Osinska, B. AU - Herholz, H. AU - Wendykowska, K. AU - Laius, O. AU - Jan, S. AU - Sermet, C. AU - Zara, C. PY - 2010 DA - 2010// TI - Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers JO - BMC Health Serv Res VL - 10 UR - https://doi.org/10.1186/1472-6963-10-153 DO - 10.1186/1472-6963-10-153 ID - Adamski2010 ER - TY - STD TI - Skjult markedsføringsinitiativ. [http://taenk.dk/dokumentation/breve/skjult-markedsf%C3%B8ringsinitiativ] UR - http://taenk.dk/dokumentation/breve/skjult-markedsf%C3%B8ringsinitiativ ID - ref4 ER - TY - STD TI - Potenspiller: Fuld tilfredshed eller pengene tilbage. [http://jp.dk/indland/article237683.ece] UR - http://jp.dk/indland/article237683.ece ID - ref5 ER - TY - CHAP AU - Persson, U. PY - 2010 DA - 2010// TI - European Market Access Environment. The Swedish Experience BT - European Market Access University Dimploma ID - Persson2010 ER - TY - JOUR AU - Willis, M. AU - Persson, U. AU - Zoellner, Y. AU - Gradl, B. PY - 2010 DA - 2010// TI - Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (duodopa(R)) in sweden JO - Appl Health Econ Health Policy VL - 8 UR - https://doi.org/10.2165/11531160-000000000-00000 DO - 10.2165/11531160-000000000-00000 ID - Willis2010 ER - TY - CHAP PY - 2008 DA - 2008// BT - Lakemedelsformansnamnden (LFN) Beslut (Decision) 0625/2006 ID - ref8 ER - TY - CHAP PY - 2006 DA - 2006// BT - Lakemedelsformansnamnden (LFN) Beslut (Decision) 1023/2006 ID - ref9 ER - TY - JOUR AU - Persson, U. AU - Willis, M. AU - Odegaard, K. PY - 2010 DA - 2010// TI - A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden JO - Eur J Health Econ VL - 11 UR - https://doi.org/10.1007/s10198-009-0166-1 DO - 10.1007/s10198-009-0166-1 ID - Persson2010 ER - TY - CHAP PY - 2010 DA - 2010// BT - Avis de la Commission de la transparence. RISPERDALCONSTA L.P ID - ref11 ER - TY - CHAP AU - Renaudin, M. N. PY - 2010 DA - 2010// TI - Risk Sharing for Reimbursement and Pricing of Drugs BT - ISPOR Connections ID - Renaudin2010 ER - TY - CHAP PY - 2010 DA - 2010// BT - Oncology registries ID - ref13 ER - TY - CHAP AU - Gallo, P. F. PY - 2008 DA - 2008// TI - Pharmaceutical risk-sharing and conditional reimbursement in Italy BT - Central and Eastern European Society of Technology Assessment in Health Care (CEESTAHC) ID - Gallo2008 ER - TY - CHAP AU - Jommi, C. PY - 2010 DA - 2010// BT - Central and regional policies affecting drugs market access in Italy ID - Jommi2010 ER - TY - CHAP PY - 2000 DA - 2000// BT - Protocollo di monitoraggio dei piani di trattamento farmacologico per la malattia di Alzheimer ID - ref16 ER - TY - CHAP PY - 2008 DA - 2008// BT - La pratica clinica mette alla prova l'innovazione terapeutica: l'esempio "ivabradina" ID - ref17 ER - TY - CHAP PY - 2008 DA - 2008// BT - Incretine: il sistema di monitoraggio dell'AIFA ID - ref18 ER - TY - CHAP PY - 2007 DA - 2007// BT - Criteri di valutazione per l'attribuzione del grado di innovazione terapeutica ai farmaci appartenenti a ciascuna delle tre classi della gravità della malattia bersaglio si considerano: la disponibilità di trattamenti preesistenti; l'entità dell'effetto terapeutico ID - ref19 ER - TY - CHAP PY - 2010 DA - 2010// BT - List of patient access schemes approved as part of a NICE appraisal ID - ref20 ER - TY - STD TI - Towse A: Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?. Br J Clin Pharmacol. 70: 360-366. ID - ref21 ER - TY - CHAP PY - 2009 DA - 2009// BT - The 2009 Pharmaceutical Price Regulation Scheme ID - ref22 ER - TY - CHAP AU - Thorp, H. AU - Hughes, C. PY - 2010 DA - 2010// TI - Trends in NHS funding: patient access schemes BT - Clinical Pharmacist ID - Thorp2010 ER - TY - CHAP PY - 2008 DA - 2008// BT - Erlotinib. Non small cell lung cancer TA162 ID - ref24 ER - TY - CHAP PY - 2009 DA - 2009// BT - Lenalidomide Multiple myeloma TA171 ID - ref25 ER - TY - CHAP PY - 2008 DA - 2008// BT - Ranibizumab Acute wet macular degeneration TA155 ID - ref26 ER - TY - CHAP PY - 2010 DA - 2010// BT - Trabectedin Advanced soft tissue sarcoma TA185 ID - ref27 ER - TY - CHAP PY - 2010 DA - 2010// BT - Gefitinib Non small cell lung cancer TA192 ID - ref28 ER - TY - CHAP PY - 2009 DA - 2009// BT - Sunitinib Advanced and/or metastatic renal cell cancer TA169 ID - ref29 ER - TY - CHAP PY - 2009 DA - 2009// BT - Sunitinib Gastrointestinal stromal tumours TA179 ID - ref30 ER - TY - CHAP PY - 2009 DA - 2009// BT - Cetuximab Colorectal cancer TA176 ID - ref31 ER - TY - CHAP PY - 2010 DA - 2010// BT - Certolizumab Rheumatoid arthritis TA186 ID - ref32 ER - TY - CHAP PY - 2009 DA - 2009// BT - Ustekinumab Psoriasis TA180 ID - ref33 ER - TY - CHAP PY - 2007 DA - 2007// BT - Bortezomib Multiple myeloma TA129 ID - ref34 ER - TY - CHAP PY - 2011 DA - 2011// BT - Myelodysplastic syndromes - azacitidine TA218 ID - ref35 ER - TY - CHAP PY - 2011 DA - 2011// BT - Renal cell carcinoma (first line metastatic) - pazopanib TA215 ID - ref36 ER - TY - CHAP PY - 2002 DA - 2002// BT - Cost effective provision of disease modifying therapies for people with multiple sclerosis ID - ref37 ER - TY - JOUR AU - Jaroslawski, S. AU - Toumi, M. PY - 2011 DA - 2011// TI - Design of Patient Access Schemes in the UK: Influence of Health Technology Assessment by the National Institute for Health and Clinical Excellence JO - Appl Health Econ Health Policy VL - 9 UR - https://doi.org/10.2165/11592960-000000000-00000 DO - 10.2165/11592960-000000000-00000 ID - Jaroslawski2011 ER - TY - JOUR AU - de Pouvourville, G. PY - 2006 DA - 2006// TI - Risk-sharing agreements for innovative drugs: a new solution to old problems? JO - Eur J Health Econ VL - 7 UR - https://doi.org/10.1007/s10198-006-0386-6 DO - 10.1007/s10198-006-0386-6 ID - de Pouvourville2006 ER - TY - JOUR AU - Towse, A. AU - Garrison, L. P. PY - 2010 DA - 2010// TI - Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products JO - Pharmacoeconomics VL - 28 UR - https://doi.org/10.2165/11314080-000000000-00000 DO - 10.2165/11314080-000000000-00000 ID - Towse2010 ER - TY - STD TI - Avis de la Commission de la transparence. AVANDIA. 2010, Paris: Haute Authorite de Sante ID - ref41 ER - TY - CHAP AU - Grubert, N. PY - 2009 DA - 2009// TI - The Pricing and Reimbursement Environment for Neurology Drugs BT - Spectrum ID - Grubert2009 ER - TY - JOUR AU - Pickin, M. AU - Cooper, C. L. AU - Chater, T. AU - O'Hagan, A. AU - Abrams, K. R. AU - Cooper, N. J. AU - Boggild, M. AU - Palace, J. AU - Ebers, G. AU - Chilcott, J. B. PY - 2009 DA - 2009// TI - The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future JO - BMC Neurol VL - 9 UR - https://doi.org/10.1186/1471-2377-9-1 DO - 10.1186/1471-2377-9-1 ID - Pickin2009 ER - TY - CHAP PY - 2009 DA - 2009// BT - A Report into the Uptake of Patient Access Schemes in the NHS ID - ref44 ER - TY - JOUR AU - Williamson, S. PY - 2010 DA - 2010// TI - Patient access schemes for high-cost cancer medicines JO - Lancet Oncology VL - 11 UR - https://doi.org/10.1016/S1470-2045(09)70402-4 DO - 10.1016/S1470-2045(09)70402-4 ID - Williamson2010 ER - TY - CHAP AU - Jack, A. PY - 2010 DA - 2010// TI - NHS drugs adviser questions price policy BT - Financial Times ID - Jack2010 ER - TY - CHAP AU - Jack, A. PY - 2010 DA - 2010// TI - Italy to cut cost of cancer drugs BT - Financial Times ID - Jack2010 ER - TY - CHAP PY - 2004 DA - 2004// BT - Progetto Cronos: i risultati dello studio osservazionale ID - ref48 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6963/11/259/prepub UR - http://www.biomedcentral.com/1472-6963/11/259/prepub ID - ref49 ER -